Our Story
Tackling twin scourges of humanity
Humanity is continuously challenged by global disease burden from AMR and cancers. Available therapies are unable to address many of these issues. We are a group of highly experienced scientists with a single focus agenda to provide novel solutions to these health threats.
New antibacterial (AB) and immuno-oncology (IO) interventions are urgently needed.
Our Therapy Areas
Immuno-Oncology
Stepping up Immunotherapy to the next level:
Tapping the Tumor Microenvironment
Our research programs focus on discovering affordable, differentiated, small molecule therapeutics for highly hypoxic tumors where adenosine plays a pivotal role in creating an immunosuppressive and tumor promoting environment.
Antibacterial Agents
Discovery of novel antibacterial agents:
Innovative solutions to combat AMR
Our solutions are products of sophisticated technologies with the potential to cover a broad range of priority pathogens in the syndromes of high unmet need, addressing many serious hospital and community infections and combating a broad spectrum of biothreat pathogens.
Project Portfolio
A key gap in the recently approved drugs, as well as those in late-stage pipeline, is the lack of oral options that cover Gram-Negative and Gram-Positive microbial infections. An intravenous and oral drug product will address the treatment of Gram-Negative and Gram-Positive infections implied in HABP/VABP, CABP, uUTI, cUTI, and other enteric infections.
Modulating the immune system through a small molecule approach offers several unique advantages that are complementary to, and potentially synergistic with, biologic modalities and are poised to significantly extend the scope of immuno-oncology applications and enhance the opportunities for combination with tumour-targeted agents and biologic immunotherapies.
Pipeline
Our pipeline consists of targeted small molecules for the treatment of multidrug-resistant microbial infections and hypoxic, immunosuppressed, refractory solid tumors.
About Us
Bugworks was set up in 2014 and incubated in C-CAMP, Bangalore. The core scientific team comes with a combined experience of over 200 years in Drug Discovery. Bugworks engages with multiple, globally reputed partners to propel its breakthrough broad-spectrum assets.
News & Announcements
Bugworks and GARDP join forces to accelerate development of a novel antibiotic to treat serious bacterial infections.
July 28, 2023 Published in GARDP
An engaging and informative podcast titled “What can we do to stop superbugs?” by Dr Anand Anandkumar, CEO with Alisha Wainwright onbehalf of Wellcome Trust.
June 28, 2023 Published in Wellcome Trust
Dr Santanu Datta and Vasan Sambandamurthy from Bugworks have contributed a chapter titled “Bugworks is a beacon of hope in the discovery of novel antibacterial agents” in the book “No Option: The Hidden Crisis and Hope for AMR“ presented by the AMR Declaration Trust.
June 22, 2023 Published in book by AMR DECLARATION TRUST
An article by Leela Maitreyi, Director, “Antimicrobial Resistance And Its Impact On Public Health”.
June 09, 2023 Published in Indiatimes
